Habiba Kamal

Dr. Habiba Kamal


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2020 in Hepatology
Verified
Journal Article
Open access
PDF file
HKHabiba Kamal
Habiba Kamal
GWGabriel Westman
Gabriel Westman
KFKarolin Falconer
Karolin Falconer
ADAnn‐Sofi Duberg
Ann‐Sofi Duberg
OWOla Weiland
Ola Weiland
SASoo Aleman
Soo Aleman
Background and Aims: Hepatitis delta virus (HDV) infection is associated with fast progression to liver cirrhosis and liver complications. Previous studies have, however, been mainly from tertiary care centers, with risk for referral bias toward patients with worse outcomes. Furthermore, the impact of HDV viremia per se on liver‐related outcomes is not really known outside the human immunodeficiency virus co‐infection setting. We have therefore evaluated the long‐term impact of HDV viremia on liver‐related outcomes in a nationwide cohort of patients with hepatitis B and D co‐infection, cared for at secondary care centers in Sweden. Approach and Results: In total, 337 patients with anti‐HDV positivity, including 233 patients with HDV RNA viremia and 91 without HDV viremia at baseline, were retrospectively studied, with a mean follow‐up of 6.5 years (range, 0.5‐33.1). The long‐term risks for liver‐related events (i.e., hepatocellular carcinoma [HCC], hepatic decompensation, or liver‐related death/transplantation) were assessed, using Cox regression analysis. The risk for liver‐related events and HCC was 3.8‐fold and 2.6‐fold higher, respectively, in patients with HDV viremia compared with those without viremia, although the latter was not statistically significant. Among patients with HDV viremia with no baseline cirrhosis, the cumulative risk of being free of liver cirrhosis or liver‐related events was 81.9% and 64.0% after 5 and 10 years of follow‐up, respectively. This corresponds to an incidence rate of 0.04 cases per person‐year. Conclusions: HDV RNA viremia is associated with a 3.8‐fold higher risk for liver‐related outcomes. The prognosis was rather poor for patients with HDV viremia without cirrhosis at baseline, but it was nevertheless more benign than previous estimates from tertiary centers. Our findings may be of importance when making decisions about treatment and evaluating potential outcomes of upcoming antivirals against HDV.

29 June 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
TSTakuya Sekine
Takuya Sekine
APAndré Perez-Potti
André Perez-Potti
OROlga Rivera-Ballesteros
Olga Rivera-Ballesteros
KSKristoffer Strålin
Kristoffer Strålin
JGJean-Baptiste Gorin
Jean-Baptiste Gorin
MBMarcus Buggert
Marcus Buggert
SARS-CoV-2-specific memory T cells will likely prove critical for long-term immune protection against COVID-19. We systematically mapped the functional and phenotypic landscape of SARS-CoV-2-specific T cell responses in a large cohort of unexposed individuals as well as exposed family members and individuals with acute or convalescent COVID-19. Acute phase SARS-CoV-2-specific T cells displayed a highly activated cytotoxic phenotype that correlated with various clinical markers of disease severity, whereas convalescent phase SARS-CoV-2-specific T cells were polyfunctional and displayed a stem-like memory phenotype. Importantly, SARS-CoV-2-specific T cells were detectable in antibody-seronegative family members and individuals with a history of asymptomatic or mild COVID-19. Our collective dataset shows that SARS-CoV-2 elicits robust memory T cell responses akin to those observed in the context of successful vaccines, suggesting that natural exposure or infection may prevent recurrent episodes of severe COVID-19 also in seronegative individuals.

28 July 2021 in Journal of Viral Hepatitis
Verified
Journal Article
Open access
HKHabiba Kamal
Habiba Kamal
RFRomina Fornes
Romina Fornes
JSJohanna Simin
Johanna Simin
PSPer Stål
Per Stål
ADAnn‐Sofi Duberg
Ann‐Sofi Duberg
SASoo Aleman
Soo Aleman
Hepatitis D virus (HDV) infection causes a severe chronic viral hepatitis with accelerated development of liver cirrhosis and decompensation, but whether it further increases the risk of hepatocellular carcinoma (HCC) is unclear. We performed a comprehensive systematic review of the published literature and meta‐analysis to assess the risk of HCC in HDV and hepatitis B virus (HBV) co‐infected, compared to HBV mono‐infected patients. The study was conducted per a priori defined protocol, including only longitudinal studies, thus excluding cross‐sectional studies. Random‐effects models were used to determine aggregate effect sizes (ES) with 95% confidence intervals (CI). Meta‐regression was used to examine the associations among study level characteristics. Twelve cohort studies comprising a total of 6099 HBV/HDV co‐infected and 57,620 chronic HBV mono‐infected patients were analysed. The overall pooled ES showed that HBV/HDV co‐infected patients were at 2‐fold increased risk of HCC compared to HBV mono‐infected patients (ES = 2.12, 95% CI 1.14–3.95, I2 = 72%, N = 12). A six‐fold significant increased risk of HCC was noted among HIV/HBV/HDV triple‐infected, compared to HIV/HBV co‐infected patients. The magnitude of ES did not differ significantly after adjustment for study design and quality, publication year and follow‐up duration in univariable meta‐regression analysis. This systematic review and meta‐analysis shows that infection with HDV is associated with a 2‐fold higher risk of HCC development compared to HBV mono‐infection. HCC surveillance strategies taking this increased risk into account, and new treatment options against HDV, are warranted.

21 May 2021 in Hepatology
Verified
Journal Article
Open access
PDF file
HKHabiba Kamal
Habiba Kamal
OSOmid Sadr‐Azodi
Omid Sadr‐Azodi
LELars Engstrand
Lars Engstrand
NBNele Brusselaers
Nele Brusselaers
Background and Aims: Biliary tract cancer is a group of highly aggressive malignant disorders, yet risk factors are poorly understood. In this study, we aim to assess whether prolonged use of proton pump inhibitors (PPIs) increases the risk of incident biliary tract carcinoma in a nation‐wide population‐based cohort in Sweden. Approach and Results: Using nation‐wide registries, we identified all adults who received maintenance PPIs (≥180 days) according to the Swedish Prescribed Drug Register from 2005 through 2012. Data on incident biliary tract cancer were retrieved from the Swedish Cancer, Death and Outpatient Registers. Risk of biliary tract cancer in persons who received PPI treatment was compared with the general population of the corresponding age, sex, and calendar year yielding standardized incidence ratios (SIRs) with 95% CIs. Of 738,881 PPI users (median follow‐up of 5.3 years), 206 (0.03%) developed gallbladder cancer and 265 (0.04%) extrahepatic and 131 (0.02%) intrahepatic bile duct cancer corresponding to SIRs of 1.58 (95% CI, 1.37‐1.81), 1.77 (95% CI, 1.56‐2.00), and 1.88 (95% CI, 1.57‐2.23), respectively. In sensitivity analyses restricted to persons without a history of gallstones or chronic liver or pancreatic diseases, SIRs were 1.36 (95% CI, 1.17‐1.57) and 1.47 (95% CI, 1.19‐1.80) for extra‐ and intrahepatic duct cancer, respectively. The risk remained higher than the corresponding general population with ≥5 years of PPIs use, ruling out confounding by indication. Conclusions: In this study, long‐term use of PPIs was associated with an increased risk of gallbladder, intrahepatic, and extrahepatic bile duct cancer compared with the general population.

11 November 2022 in Liver International
Verified
Journal Article
Open access
HKHabiba Kamal
Habiba Kamal
SASoo Aleman
Soo Aleman
DCD‐SOLVE Consortium
D‐SOLVE Consortium
A severe course has been described in early studies on chronic hepatitis D (CHD), with faster pace towards liver cirrhosis with subsequent high liver‐related morbidity and mortality in the majority of patients. Earlier studies have included risk groups as people using intravenous drugs (PWID) or those with multiple co‐morbidities. During the last decade, the epidemiological landscape of CHD has changed with domestic cases decreasing while increasing cases of CHD consisting of younger persons immigrating from endemic regions to low‐endemic regions. Recently, further insights into the spectrum of the disease with an indolent disease course in a substantial proportion of persons with CHD have been gained. At diagnosis, ≥30%–50% had already established liver cirrhosis. Older age, liver cirrhosis, co‐infection with HIV and lack of interferon (IFN) therapy are the main predictors of worse clinical outcome. The newly introduced and upcoming antivirals against CHD are highly anticipated, considering the historically low virological response rates to antiviral therapy. Further knowledge is needed to fully comprehend the natural course and the spectrum of this severe form of viral hepatitis. This is also to be able to evaluate the long‐term effects of the new antivirals on disease progression.

1 December 2023 in Hepatology Communications
Verified
Journal Article
Open access
HKHabiba Kamal
Habiba Kamal
MIMichael Ingre
Michael Ingre
PSPer I Stål
Per I Stål
GWGabriel Westman
Gabriel Westman
DBDaniel Bruce
Daniel Bruce
SASoo Aleman
Soo Aleman
Background: The international recommendations of HCC surveillance for African-born persons with chronic hepatitis B (CHB) without cirrhosis are divergent, probably due to scarce data on incidence rate (IR) for HCC. Methods: We assembled a cohort with prospectively collected data of Swedish residents of African origin with diagnosed CHB without cirrhosis at baseline from 1990 to 2015. Data from nationwide registers were used to calculate the sex-specific IR and IR ratio (incidence rate ratios) in relation to age, comorbidities, and birth region, using a generalized linear model with a log-link function and Poisson distribution. Results: Among 3865 African-born persons with CHB without cirrhosis at baseline, 31 (0.8%; 77.4% men) developed HCC during a median of 11.1 years of follow-up, with poor survival after HCC diagnosis. The mean age at HCC diagnosis was 46.8 (SD±14.7; range 23–79) in men. HCC IR exceeded the recommended surveillance threshold of 0.2%/year at ages 54 and 59 years in men and women, respectively, and at ages 20–40 years if HCV or HDV co-infection was present. African-born men with CHB had an incidence rate ratios of 10.6 (95% CI 4.4–31.5) for HCC compared to matched African-born peers without CHB, and an incidence rate ratios of 35.3 (95% CI 16.0–88.7) compared to a matched general population. Conclusions: African-born men with CHB without cirrhosis reached an IR of 0.2%/year between 50 and 60 years, and at younger ages if HCV or HDV co-infection was present. Our findings need further confirmation, and new cost-effectiveness analyses specific for young populations are needed, to provide personalized and cost-effective HCC surveillance.